http://www.ncbi.nlm.nih.gov/pubmed/25245366A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.
Dorff TB1, Groshen S2, Tsao-Wei DD2, Xiong S3, Gross ME4, Vogelzang N5, Quinn DI6, Pinski JK6.
1Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
2Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
3Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
4Keck School of Medicine, Westside Prostate Cancer Center, Center for Applied Molecular Medicine, University of Southern California, Los Angeles, CA, USA.
5Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
6Division of Medical Oncology, Department of Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Men with biochemical recurrence (BCR) of prostate cancer are typically observed or treated with androgen-deprivation therapy. Non-hormonal, non-toxic treatments to slow the rise of PSA are desirable. We studied a combination herbal supplement, Prostate Health Cocktail (PHC), in prostate cancer cell lines and in a population of men with BCR.
PC3, LAPC3 and LNCaP cells were incubated with increasing concentrations of PHC suspension. Men previously treated for prostate cancer with surgery, radiation or both with rising PSA but no radiographic metastases were treated with three capsules of PHC daily; the primary end point was 50% PSA decline. Circulating tumor cells (CTCs) were identified using parylene membrane filters.
PHC showed a strong dose-dependent anti-proliferative effect in androgen-sensitive and independent cell lines in vitro and suppression of androgen receptor expression. Forty eligible patients were enrolled in the clinical trial. Median baseline PSA was 2.8 ng ml(-1) (1.1-84.1) and 15 men (38%) had a PSA decline on study (1-55% reduction); 25 (62%) had rising PSA on study. The median duration of PSA stability was 6.4 months. Two patients had grade 2/3 transaminitis; the only other grade 2 toxicities were hyperglycemia, hypercalcemia and flatulence. There were no significant changes in testosterone or dihydrotestosterone. CTCs were identified in 19 men (47%).
Although the primary end point was not met, PHC was well tolerated and was associated with PSA declines and stabilization in a significant number of patients. We believe this is the first report of detecting CTCs in men with BCR prostate cancer. Randomized studies are needed to better define the effect of PHC in men with BCR.
Foro general ciencia, medicina, nutrición, salud pública, política
1 mensaje • Página 1 de 1
- Administrador del Sitio
- Mensajes: 6512
- Registrado: Dom, 01 Sep 2013, 14:18
- Ubicación: Madrid
Esto, y la investigación con vitamina D y tantas otras cosas potenciales y baratas y sin efectos secundarios que servirían para eliminar células cancerosas al menos en estadio temprano, eliminaría a su vez el problema de sobrediagnóstico de cancer de próstata, y las consecuentes salvajadas médicas que se hacen por una PSA con una correlación como la de lanzar una moneda al aire.